Pair Name | Tubeimoside I, Temozolomide | ||
Phytochemical Name | Tubeimoside I (PubChem CID: 6110917 ) | ||
Anticancer drug Name | Temozolomide (PubChem CID: 5394 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Tubeimoside I, Temozolomide | |||
Disease Info | [ICD-11: 2A00] | Glioblastoma multiforme | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Down-regulation | Expression | EGFR | hsa1956 | |
Down-regulation | Expression | MGMT | hsa4255 | |
Down-regulation | Phosphorylation | MTOR | hsa2475 | |
Down-regulation | Phosphorylation | NFKB1 | hsa4790 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Down-regulation | Phosphorylation | PIK3CA | hsa5290 | |
Down-regulation | Phosphorylation | RELA | hsa5970 | |
Down-regulation | Phosphorylation | RHOBTB2 | hsa23221 | |
In Vitro Model | U-118MG | Astrocytoma | Homo sapiens (Human) | CVCL_0633 |
T98G | Glioblastoma | Homo sapiens (Human) | CVCL_0556 | |
Result | We first demonstrated that synergistic effects of TBMS1 and TMZ induced apoptosis in GBM cells through reducing MGMT expression and inhibiting the EGFR induced PI3K/Akt/mTOR/NF-κB signaling pathway. This study provides a rationale for combined application of TMZ and TBMS1 as a potential chemotherapeutic treatment for MGMT+ GBM patients. |
No. | Title | Href |
---|---|---|
1 | Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway. Phytomedicine. 2022 May;99:154016. doi: 10.1016/j.phymed.2022.154016. | Click |